Newspaper article

Mon patient est trop âgé pour une statine : mythes et réalités

Published inRevue médicale suisse, vol. 11, no. 494, p. 2110-2114
Publication date2015

Lipid-lowering treatment in the elderly patient is conditioned by a high incidence and prevalence of cardiovascular disease in the setting of a limited remaining life span. The clinical benefit of statin therapy can be seen after a few months, thus supporting use in secondary prevention even when the lifespan is restricted to a few years. Recent guidelines propose the use of moderate doses in the elderly > 75 years. The evidence for treatment in primary prevention is weaker and the evaluation of the total cardiovascular risk is complicated by the high baseline risk of many elderly. Rational treatment decisions should be based on biologic rather than chronologic age. Statins are generally well tolerated in the elderly, requiring clinical monitoring only, with particular attention to pharmacokinetic interactions and renal failure.

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Algorithms
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors/contraindications
  • Hypolipidemic Agents/contraindications
Citation (ISO format)
STEENPASS, Veronika et al. Mon patient est trop âgé pour une statine : mythes et réalités. In: Revue médicale suisse, 2015, vol. 11, n° 494, p. 2110–2114.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation11/29/2016 2:56:00 PM
First validation11/29/2016 2:56:00 PM
Update time03/15/2023 1:06:02 AM
Status update03/15/2023 1:06:01 AM
Last indexation05/02/2024 6:00:40 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack